Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.96 USD | +1.08% | -0.98% | -23.35% |
05-10 | UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating | MT |
05-10 | Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.35% | 2.06B | |
+4.50% | 109B | |
+11.21% | 105B | |
+0.82% | 22.25B | |
-11.74% | 22.09B | |
-8.05% | 18.68B | |
-38.36% | 17.58B | |
-10.24% | 16.85B | |
+4.74% | 13.76B | |
+37.92% | 12.46B |
- Stock Market
- Equities
- RCKT Stock
- News Rocket Pharmaceuticals, Inc.
- Canaccord Genuity Adjusts Price Target on Rocket Pharmaceuticals to $47 From $49, Maintains Buy Rating